Active substance | Tafasitamab |
Holder | Clinigen Healthcare Ltd on behalf of Incyte Ltd |
Status | closed |
Indication | the treatment of adult patients who have Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and who are not eligible for autologous stem cell transplantation (ASCT) |
Public documents | Approbation |
Information for the patient | |
Informed consent | |
Last update | 26/10/2023 |